SHOULD CANADA AND THE UNITED-STATES UNIVERSALLY VACCINATE INFANTS AGAINST HEPATITIS-B

被引:56
作者
KRAHN, M [1 ]
DETSKY, AS [1 ]
机构
[1] UNIV TORONTO,DEPT HLTH ADM & MED,TORONTO M5S 1A1,ONTARIO,CANADA
关键词
VACCINATION; HEPATITIS-B; COST EFFECTIVENESS; PREVENTION; CHRONIC HEPATITIS;
D O I
10.1177/0272989X9301300103
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This paper examines the economic attractiveness of universal vaccination of infants with hepatitis B virus (HBV) vaccine by calculating the incremental cost-effectiveness of this strategy when compared with the currently recommended strategy of screening all pregnant women and vaccinating only infants born to HBsAg+ mothers. A decision-analytic model involving a Markov process to model the long-term sequelae of HBV infection was constructed to estimate the expected costs and life expectancies for a cohort of newborns under two strategies: the current screening policy (SELECTIVE), which involves active and passive vaccination of infants born to carrier mothers, and a policy that combines the current screening strategy (including active and passive vaccination of infants born to carriers) with active vaccination alone for children of non-carriers (UNIVERSAL). A hypothetical cohort of children born in either Canada or the United States in 1991 was examined. Cost estimates were derived for Ontario. From a societal perspective, the incremental cost required to achieve one extra life year was found to be $30,347, comparable to the cost-effectivenesses of other health care strategies commonly used in North America. The result is sensitive to the duration of vaccine effectiveness and particularly to the price of the vaccine. Universal vaccination results in net cost saving at a vaccine price of approximately $7 per dose, from a societal perspective. It is concluded that universal vaccination against HBV in infancy is economically attractive, comparable in cost-effectiveness to existing health care interventions. Lower vaccine prices would substantially improve the attractiveness of such a program. Implementation of universal vaccination should be considered in North America, contingent on vaccine price reduction. A monitoring program to ensure the long-term efficacy of the vaccine should be part of such a program.
引用
收藏
页码:4 / 20
页数:17
相关论文
共 80 条
[1]   THE EFFECT OF UNDERREPORTING ON THE APPARENT INCIDENCE AND EPIDEMIOLOGY OF ACUTE VIRAL-HEPATITIS [J].
ALTER, MJ ;
MARES, A ;
HADLER, SC ;
MAYNARD, JE .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1987, 125 (01) :133-139
[2]   THE CHANGING EPIDEMIOLOGY OF HEPATITIS-B IN THE UNITED-STATES - NEED FOR ALTERNATIVE VACCINATION STRATEGIES [J].
ALTER, MJ ;
HADLER, SC ;
MARGOLIS, HS ;
ALEXANDER, WJ ;
HU, PY ;
JUDSON, FN ;
MARES, A ;
MILLER, JK ;
MOYER, LA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (09) :1218-1222
[3]   THE LONG-TERM SEROLOGICAL COURSE OF ASYMPTOMATIC HEPATITIS-B VIRUS CARRIERS AND THE DEVELOPMENT OF PRIMARY HEPATOCELLULAR-CARCINOMA [J].
ALWARD, WLM ;
MCMAHON, BJ ;
HALL, DB ;
HEYWARD, WL ;
FRANCIS, DP ;
BENDER, TR .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (04) :604-609
[4]  
BARIN F, 1982, LANCET, V1, P251
[5]  
Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209
[6]  
BEASLEY RP, 1983, HEPATOLOGY, V3, P135
[7]   E-ANTIGEN AND VERTICAL TRANSMISSION OF HEPATITIS-B SURFACE-ANTIGEN [J].
BEASLEY, RP ;
TREPO, C ;
STEVENS, CE ;
SZMUNESS, W .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1977, 105 (02) :94-98
[8]  
BEASLEY RP, 1983, LANCET, V2, P1099
[9]  
BEASLEY RP, 1981, LANCET, V2, P388
[10]  
BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO